Friday November 27 2009 | Biotechnology feed | All feeds
|
|
Zenyth Therapeutics Limited
Download detailed PDF Members: Zenyth Therapeutics Limited (Zenyth) is a public listed (ASX: ZTL) Australian biotechnology company primarily focused on the development and commercialisation of antibody-based therapies in the areas of inflammation and cancer. Zenyth has intellectual property rights to a number of key molecules which have pivotal roles in cancer and inflammatory diseases including rheumatoid arthritis and asthma. Zenyth’s scientific team has expertise in antibody generation and engineering and works closely with academic medical research institutes as well as local and international pharmaceutical and biotechnology companies to advance therapies from the discovery phase through to commercialisation. Zenyth’s current corporate partners include Merck and Co., Inc., Cambridge Antibody Technology, MuriGen Therapeutics and Medarex Inc. In addition, Zenyth has an antibody library licence agreement with Dyax Corporation.
This page has been viewed 591 times since April 2007, the link to the organisation's website has been followed 99 times Recent Search Terms used to find this page: zenyth therapeutics | merk zenyth deal | zenyth therapeutics | zenyth therapeutics | Merck Co and Zenyth Therapeutics | zenyth richmond | zenyth richmond | drugs developed by zenyth | Zenyth | Zenyth Therapeutics Limited | . Search for more companies in Richmond Search for more companies in Victoria This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified. BioPortfolio search results for Zenyth Therapeutics Limited | |||||||||||||||||||||||||||||||||||||||||||||||||
|